Martek Biosciences Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 639

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.08B

  • Investors
  • 1

Martek Biosciences General Information


The company is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life’sDHAâ"¢, a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in infant formula, perinatal products, foods and beverages and dietary supplements, and ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. NUTRITIONAL PRODUCTS We have developed production methods and intellectual property for two important fatty acids. These fatty acids are DHA and ARA. We sell oils containing these fatty acids under the names DHASCO®,Neuromins® and ARASCO®. We derive DHA from microalgae and ARA from fungi, using proprietary processes. Cell membranes throughout the body contain these fatty acids, and they are particularly concentrated in the brain, central nervous system, retina and heart.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
DSM Apps
Primary Office
  • 6480 Dobbin Rd
  • Columbia, MD 21045
  • United States
+1 (410) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Martek Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 28-Feb-2011 $1.08B 0000 00.000 Completed Generating Revenue
1. IPO 23-Nov-1993 0000 0000 Completed Startup
To view Martek Biosciences’s complete valuation and funding history, request access »

Martek Biosciences Patents

Martek Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20110027841-A1 Method for preparation of oxylipins Abandoned 21-Dec-2007 0000000000
US-20080234377-A1 Administering a polyunsaturated fatty acid of docosahexaenoic acid, docosapentaenoic acid, and/or arachidonic acid Abandoned 23-Mar-2007 0000000000 0
US-20080026109-A1 Sweetened oil compositions and methods of making Abandoned 29-Jun-2006 000000000 00
EP-2037746-A2 Sweetened oil compositions and methods of making Withdrawn 29-Jun-2006 000000000
EP-2037746-A4 Sweetened oil compositions and methods of making Withdrawn 29-Jun-2006 A23D9/007
To view Martek Biosciences’s complete patent history, request access »

Martek Biosciences Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Martek Biosciences Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cross Atlantic Partners PE/Buyout Minority 000 0000 000000 0
To view Martek Biosciences’s complete investors history, request access »

Martek Biosciences Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0-000000 12-Feb-2010 0000000000 00000 Other Pharmaceuticals and Biotechnology 00000 000
Martek Biosciences Boulder Corporation 25-Apr-2002 Merger/Acquisition 000.00 Food Products
To view Martek Biosciences’s complete acquisitions history, request access »

Martek Biosciences Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0-000000 12-Feb-2010 000000000000000000 00000 Completed
  • 000000 00000000000
To view Martek Biosciences’s complete exits history, request access »